Logo Asphalion

SINPAIN project | Website

The SINPAIN project website has been updated with new content and a specific section dedicated to the institutions involved in the project!

The SINPAIN project website has been updated with new content and a specific section dedicated to the institutions involved in the project!
October 19, 2022

Osteoarthritis is the most common joint disorder worldwide, but there is no efficient treatment so far. Over the next 4,5 years, #SINPAIN team will strive to develop an efficient therapy to improve the quality of life for those affected and reduce the high costs associated with this condition. The objective is to create a siRNA-combined advanced therapy, which will lead to more personalised treatment options for different stages of osteoarthritis. At Asphalion we are the regulatory partner throughout the project.

At Asphalion, we are the regulatory partner throughout the project, guiding all partners in ensuring the compliance of the regulatory requirements for the development of the nanotherapeutics, establishing a regulatory roadmap at the start of the project that will be validated with the Innovation Task Force (ITF) of the EMA. The clinical development of the nanotherapeutics and CMC aspects will also have to be considered from the regulatory perspective. Finally, an ATMP classification request will be envisaged to have a clear regulatory definition of the nanotherapeutic product.

Check the website to get to know more about this EU-funded project, discover more insights and for regular updates as the project progresses:


For further information, you can also contact us at: info@asphalion.com

Search News & Events

  • Filter by category


Related news and events

BIOSPAIN | Regulatory Insights for ATMP development

This session will center around regulatory insights to accelerate the development of ATMPs with a focus on recent experiences coming from Spanish biotech companies and regulatory experts.

In2Sight | 4th annual meeting 3RS congress

At ASPHALION, we are part of the IN2SIGHT consortium, an EU-funded project, and we are delighted to be currently participating in the 4th annual meeting

Course | Regulatory aspects of vaccine development

TRANSVAC2 supported innovation for both prophylactic and therapeutic vaccine development by providing high-quality technical services across four different service platforms: Technology (for process development and GMP production), Immunocorrelates & Systems Biology, Animal models, and support for Clinical Trials. TRANSVAC also offered training courses to provide fundamental and advanced knowledge on a wide-range of vaccine development-related topics.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting